- Home
- EBON vs CVKD Comparison
EBON vs CVKD Comparison
Compare EBON & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBON | CVKD |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 20.7M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | EBON | CVKD |
|---|---|---|
| Price | $3.89 | $11.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 4.9K | ★ 43.2K |
| Earning Date | 08-15-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,337,066.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 104.28 | N/A |
| 52 Week Low | $3.00 | $8.12 |
| 52 Week High | $8.54 | $22.90 |
Technical Indicators
Market Signals| Indicator | EBON | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 51.02 |
| Support Level | $3.37 | $9.55 |
| Resistance Level | $3.89 | $12.00 |
| Average True Range (ATR) | 0.18 | 0.91 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 26.92 | 74.23 |
Price Performance
Historical ComparisonAbout EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.